查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1435081

成人血紅蛋白血症檢測市場：按群體、類型和最終用戶分類 - 全球預測 2024-2030

Adult Hemoglobinopathy Testing Market by Group (Structural Hemoglobin Variants, Thalassemia Syndromes), Type (Hb Electrophoresis, HPLC Detection, Mass Spectrometry), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

成人血紅素血症檢測市場規模預計2023年為47.2億美元，2024年達51億美元，預計2030年將達到71.8億美元，複合年成長率為6.17%。

成人血紅素血症檢測的全球市場

主要市場統計
基準年[2023] 47.2億美元
預測年份 [2024] 51億美元
預測年份 [2030] 71.8億美元
複合年成長率（%） 6.17%
成人血紅素血症檢測市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估成人血紅素血症檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對成人血紅蛋白血症測試市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、客戶群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-成人血紅素血症檢測市場的市場規模與預測是多少？

2-在成人血紅素血症測試市場的預測期內，需要考慮投資哪些產品、細分市場、應用和領域？

3-成人血紅蛋白血症檢測市場的技術趨勢和法律規範是什麼？

4-成人血紅素血症檢測市場主要供應商的市場佔有率是多少？

5-進入成人血紅素血症檢測市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 地中海貧血和鐮狀細胞疾病 (SCD) 的全球盛行率
      • 疾病的早​​期診斷和治療趨勢
      • 需要持續的新生兒篩檢計劃和準確可靠的檢測方法
    • 抑制因素
      • 成人血紅素病檢測相關的高成本
    • 機會
      • 成人血紅素病檢測方法的技術進步
      • 成人血紅蛋白病的持續研究與開發
    • 任務
      • 成人血紅素病檢測設備的技術限制
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章成人血紅素血症檢測市場（依群體）

  • 血紅素的結構變異
  • 地中海貧血症候群

第7章成人血紅素血症檢測市場：依類型

  • 血紅素電泳
  • 高效液相層析檢測
  • 質譜

第8章成人血紅素血症檢測市場：依最終用途分類

  • 醫院
  • 實驗室
  • 醫療/調查

第9章 北美和南美成人血紅素血症檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區成人血紅素血症檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲成人血紅素血症檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • ARKRAY, Inc.
    • Beckman Coulter, Inc. by Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Bluebird Bio, Inc.
    • Creative Diagnostics
    • F. Hoffmann-La Roche Ltd.
    • HORIBA Group
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • PerkinElmer, Inc.
    • Quest Diagnostics Incorporated
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Shimadzu Corporation
    • Siemens Healthineers AG
    • Sysmex Europe SE
    • Thermo Fisher Scientific Inc.
    • Tosoh Corporation
    • Trinity Biotech PLC
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-C002B1C9978F

[180 Pages Report] The Adult Hemoglobinopathy Testing Market size was estimated at USD 4.72 billion in 2023 and expected to reach USD 5.10 billion in 2024, at a CAGR 6.17% to reach USD 7.18 billion by 2030.

Global Adult Hemoglobinopathy Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.72 billion
Estimated Year [2024] USD 5.10 billion
Forecast Year [2030] USD 7.18 billion
CAGR (%) 6.17%
Adult Hemoglobinopathy Testing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Adult Hemoglobinopathy Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adult Hemoglobinopathy Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Adult Hemoglobinopathy Testing Market, highlighting leading vendors and their innovative profiles. These include ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bluebird Bio, Inc., Creative Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA Group, Illumina, Inc., Laboratory Corporation of America Holdings, Merck KGaA, PerkinElmer, Inc., Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Adult Hemoglobinopathy Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Group
    • Structural Hemoglobin Variants
    • Thalassemia Syndromes
  • Type
    • Hb Electrophoresis
    • HPLC Detection
    • Mass Spectrometry
  • End-Use
    • Hospital
    • Laboratories
    • Medical & Research Institute
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Adult Hemoglobinopathy Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adult Hemoglobinopathy Testing Market?

3. What are the technology trends and regulatory frameworks in the Adult Hemoglobinopathy Testing Market?

4. What is the market share of the leading vendors in the Adult Hemoglobinopathy Testing Market?

5. Which modes and strategic moves are suitable for entering the Adult Hemoglobinopathy Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Adult Hemoglobinopathy Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of thalassemia and sickle cell disease (SCD) worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Ongoing newborn screening programs and need for accurate and reliable testing methodologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with adult-hemoglobinopathy-testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in adult-hemoglobinopathy-testing methods
      • 5.1.3.2. Ongoing research and development on adult-hemoglobinopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations in devices used for adult-hemoglobinopathy-testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Adult Hemoglobinopathy Testing Market, by Group

  • 6.1. Introduction
  • 6.2. Structural Hemoglobin Variants
  • 6.3. Thalassemia Syndromes

7. Adult Hemoglobinopathy Testing Market, by Type

  • 7.1. Introduction
  • 7.2. Hb Electrophoresis
  • 7.3. HPLC Detection
  • 7.4. Mass Spectrometry

8. Adult Hemoglobinopathy Testing Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Laboratories
  • 8.4. Medical & Research Institute

9. Americas Adult Hemoglobinopathy Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Hemoglobinopathy Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Hemoglobinopathy Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. ARKRAY, Inc.
    • 13.1.2. Beckman Coulter, Inc. by Danaher Corporation
    • 13.1.3. Bio-Rad Laboratories, Inc.
    • 13.1.4. Bluebird Bio, Inc.
    • 13.1.5. Creative Diagnostics
    • 13.1.6. F. Hoffmann-La Roche Ltd.
    • 13.1.7. HORIBA Group
    • 13.1.8. Illumina, Inc.
    • 13.1.9. Laboratory Corporation of America Holdings
    • 13.1.10. Merck KGaA
    • 13.1.11. PerkinElmer, Inc.
    • 13.1.12. Quest Diagnostics Incorporated
    • 13.1.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 13.1.14. Shimadzu Corporation
    • 13.1.15. Siemens Healthineers AG
    • 13.1.16. Sysmex Europe SE
    • 13.1.17. Thermo Fisher Scientific Inc.
    • 13.1.18. Tosoh Corporation
    • 13.1.19. Trinity Biotech PLC
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET DYNAMICS
  • FIGURE 7. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2030 (%)
  • FIGURE 8. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STRUCTURAL HEMOGLOBIN VARIANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HB ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HPLC DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 13. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MEDICAL & RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ADULT HEMOGLOBINOPATHY TESTING MARKET LICENSE & PRICING